EHRA 24: Risk of Stroke or Embolism and AF: ARTESiA Substudy

Published: 09 Apr 2024

  • Views:

    Views Icon 291
  • Likes:

    Heart Icon 0
Average (ratings)
No ratings
Your rating

EHRA 24 - Investigator, Dr William McIntyre (Population Health Research Institute, CA) joins us to discuss the findings from a substudy of ARTESiA (NCT01938248).

ARTESiA was a randomized, parallel assignment clinical trial which aimed to assess if apixaban could reduce the risk of ischemic stroke and systemic embolism in patients with subclinical atrial fibrillation (AF) and additional risk factors for stroke. This substudy aimed to investigate the episode duration and frequency within the ARTESiA trial. Patients were classified according to the frequency and duration of their episodes of AF, and were examined in regard to absolute risk of stroke, and the interaction to see if these factors would impact the treatment benefit of apixaban for stroke reduction. 

Findings suggest that absolute risk of stroke for patients with AF episode duration of 6 minutes to an 1 hour, 1 hour to 6 hours and 6 hours to 24 hours was consistent, clustering in to about 1% per year. The treatment effect of apixaban was also found to be consistent amongst each group. When comparing patients with a AF frequency of 1-5 episodes 6 months prior to those with 6 episodes or more, absolute stroke risk and treatment effect of apixaban was also found to be consistent. 

Interview Questions:

  1. What is the importance of this substudy?
  2. What was the substudy design, and patient cohort?
  3. What are the key findings revealed at EHRA 24? 
  4. How do the findings of this substudy shed new light on the ARTESiA findings revealed at AHA 23?
  5. What are the remaining questions?
  6. What are your take-home messages?

Recorded on-site at EHRA in Berlin, 2024. 

Editor: Jordan Rance

Video Specialist: Oliver Miles

Support: This is an independent interview conducted by Radcliffe Cardiology.


You must be to comment. If you are not registered, you can register here.